S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
Bear Market Funds to Watch This Year
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
Bear Market Funds to Watch This Year
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
Bear Market Funds to Watch This Year
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
Bear Market Funds to Watch This Year

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biofrontera AG stock logo
BFRA
Biofrontera
$2.60
$2.95
$2.09
$7.54
$73.73M1.0227,512 shs7,263 shs
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
$0.02
$0.01
$4.36
$730K-1.12845,148 shs182,360 shs
KALA BIO, Inc. stock logo
KALA
KALA BIO
$6.77
-1.0%
$7.46
$5.10
$19.35
$19.26M-1.8514,034 shs9,250 shs
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$0.39
$0.19
$28.00
$906K2.19462,687 shs2.25 million shs
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
$0.94
+10.5%
$1.04
$0.79
$4.20
$23.87M1.3335,279 shs4,553 shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biofrontera AG stock logo
BFRA
Biofrontera
0.00%0.00%0.00%0.00%0.00%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
+3.68%-11.04%-21.23%-64.12%-99.64%
KALA BIO, Inc. stock logo
KALA
KALA BIO
-1.02%-8.02%-12.31%-7.39%-56.82%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
0.00%0.00%0.00%-59.18%-99.22%
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
+10.23%+6.25%-8.29%-18.19%-75.65%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/AN/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.8922 of 5 stars
3.55.00.04.41.70.80.0
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/AN/AN/AN/A
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
3.6335 of 5 stars
3.85.00.00.03.31.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
2.00
HoldN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.00
Buy$18.00165.88% Upside
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/A
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
3.50
Strong Buy$8.00746.92% Upside

Current Analyst Ratings

Latest SLGL, NEPT, EVFM, KALA, and BFRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/2/2024
KALA BIO, Inc. stock logo
KALA
KALA BIO
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$22.00 ➝ $21.00
4/1/2024
KALA BIO, Inc. stock logo
KALA
KALA BIO
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$15.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biofrontera AG stock logo
BFRA
Biofrontera
$36.19M2.04N/AN/A$0.35 per share7.43
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$18.22M0.04$1.41 per share0.01($2.64) per share-0.01
KALA BIO, Inc. stock logo
KALA
KALA BIO
$3.89M4.91N/AN/A$2.79 per share2.43
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$52.62M0.00N/AN/A($91.90) per share0.00
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
$1.55M16.98N/AN/A$1.67 per share0.57

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biofrontera AG stock logo
BFRA
Biofrontera
-$14.88M-$0.73N/AN/A-59.44%-93.31%-24.02%N/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$52.98M-$7.62N/AN/A290.81%-90.20%331.20%4/26/2024 (Estimated)
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$42.20M-$17.94N/AN/AN/AN/A-281.02%-65.57%5/14/2024 (Estimated)
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
-$27.24M-$1.01N/AN/AN/A-1,331.01%-61.52%-53.75%5/10/2024 (Estimated)

Latest SLGL, NEPT, EVFM, KALA, and BFRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/27/2024Q4 2023
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A-$0.44-$0.44-$0.44N/A$4.84 million
3/13/2024Q4 2023
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
-$0.16-$0.17-$0.01-$0.17$0.27 million$0.45 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/AN/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/A
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biofrontera AG stock logo
BFRA
Biofrontera
0.13
1.26
1.13
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A
0.13
0.10
KALA BIO, Inc. stock logo
KALA
KALA BIO
5.10
6.33
6.33
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/A
0.23
0.10
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/A
9.10
9.10

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Biofrontera AG stock logo
BFRA
Biofrontera
60.07%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.22%
KALA BIO, Inc. stock logo
KALA
KALA BIO
24.61%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
14.44%
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
26.18%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Biofrontera AG stock logo
BFRA
Biofrontera
13828.36 millionN/ANot Optionable
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
3553.96 million53.85 millionNot Optionable
KALA BIO, Inc. stock logo
KALA
KALA BIO
432.82 million2.44 millionNot Optionable
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
584.53 million4.30 millionNot Optionable
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
3627.86 million9.33 millionOptionable

SLGL, NEPT, EVFM, KALA, and BFRA Headlines

SourceHeadline
Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 17.8% in MarchSol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 17.8% in March
americanbankingnews.com - April 15 at 5:40 AM
Sol-Gels Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® CreamSol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
globenewswire.com - April 1 at 7:00 AM
Sol Gel Technologies Ltd (SLGL)Sol Gel Technologies Ltd (SLGL)
investing.com - March 23 at 11:58 AM
SLGL May 2024 2.500 putSLGL May 2024 2.500 put
finance.yahoo.com - March 16 at 1:25 PM
Sol-Gel Technologies: Q4 Earnings InsightsSol-Gel Technologies: Q4 Earnings Insights
benzinga.com - March 14 at 1:48 PM
Sol-Gel Technologies Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineSol-Gel Technologies Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
finance.yahoo.com - March 14 at 8:47 AM
Sol-Gel Technologies Ltd.: Sol-Gel Reports Full-Year 2023 Financial Results and Corporate DevelopmentsSol-Gel Technologies Ltd.: Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
finanznachrichten.de - March 14 at 3:47 AM
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate DevelopmentsSol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
globenewswire.com - March 13 at 7:00 AM
Sol-Gel Technologies Ltd. (SLGL) stock forecast and price targetSol-Gel Technologies Ltd. (SLGL) stock forecast and price target
finance.yahoo.com - February 28 at 9:43 AM
Sol-Gel Technologies Stock (NASDAQ:SLGL), Quotes and News SummarySol-Gel Technologies Stock (NASDAQ:SLGL), Quotes and News Summary
benzinga.com - February 22 at 10:05 AM
Optimistic Buy Rating for Sol-Gel Technologies on Revolutionary Topical Treatment SGT-610’s Market PotentialOptimistic Buy Rating for Sol-Gel Technologies on Revolutionary Topical Treatment SGT-610’s Market Potential
markets.businessinsider.com - December 9 at 3:48 AM
Sol-Gel Technologies Ltd.: Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 StudySol-Gel Technologies Ltd.: Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
finanznachrichten.de - November 30 at 6:30 PM
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 StudySol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
finance.yahoo.com - November 30 at 8:29 AM
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
finance.yahoo.com - November 28 at 9:36 AM
Is Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 24% Discount?Is Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 24% Discount?
finance.yahoo.com - November 20 at 7:19 AM
Sol-Gel Technologies GAAP EPS of -$0.21 beats by $0.02, revenue of $0.21M misses by $0.48MSol-Gel Technologies GAAP EPS of -$0.21 beats by $0.02, revenue of $0.21M misses by $0.48M
msn.com - November 9 at 5:31 PM
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateSol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 7:27 AM
Zacks Industry Outlook Highlights Dr. Reddys Laboratories, Amphastar Pharmaceuticals and Sol-Gel TechnologiesZacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies
finance.yahoo.com - October 31 at 9:35 AM
Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Invest In Growth?Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Invest In Growth?
finance.yahoo.com - October 10 at 10:05 AM
Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceSol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
finance.yahoo.com - August 30 at 2:55 PM
HC Wainwright & Co. Maintains Sol-Gel Technologies (SLGL) Buy RecommendationHC Wainwright & Co. Maintains Sol-Gel Technologies (SLGL) Buy Recommendation
msn.com - August 15 at 5:07 AM
Expert Ratings for Sol-Gel TechnologiesExpert Ratings for Sol-Gel Technologies
markets.businessinsider.com - August 11 at 4:26 PM
Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue EstimatesSol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 10 at 2:04 PM
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateSol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
finance.yahoo.com - August 10 at 9:03 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Biofrontera logo

Biofrontera

NASDAQ:BFRA
Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.
Evofem Biosciences logo

Evofem Biosciences

NASDAQ:EVFM
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
KALA BIO logo

KALA BIO

NASDAQ:KALA
KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Neptune Wellness Solutions logo

Neptune Wellness Solutions

NASDAQ:NEPT
Neptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada.
Sol-Gel Technologies logo

Sol-Gel Technologies

NASDAQ:SLGL
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610, a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.